These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 23192887)
1. Selective induction of TP53I3/p53-inducible gene 3 (PIG3) in myeloid leukemic cells, but not in normal cells, by Nutlin-3. Voltan R; Secchiero P; Corallini F; Zauli G Mol Carcinog; 2014 Jun; 53(6):498-504. PubMed ID: 23192887 [TBL] [Abstract][Full Text] [Related]
2. Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells. Secchiero P; Zerbinati C; di Iasio MG; Melloni E; Tiribelli M; Grill V; Zauli G Curr Drug Metab; 2007 May; 8(4):395-403. PubMed ID: 17504227 [TBL] [Abstract][Full Text] [Related]
3. The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status. Zauli G; Celeghini C; Melloni E; Voltan R; Ongari M; Tiribelli M; di Iasio MG; Lanza F; Secchiero P Haematologica; 2012 Nov; 97(11):1722-30. PubMed ID: 22689683 [TBL] [Abstract][Full Text] [Related]
4. 1,25-dihydroxyvitamin D3 enhances the apoptotic activity of MDM2 antagonist nutlin-3a in acute myeloid leukemia cells expressing wild-type p53. Thompson T; Andreeff M; Studzinski GP; Vassilev LT Mol Cancer Ther; 2010 May; 9(5):1158-68. PubMed ID: 20406950 [TBL] [Abstract][Full Text] [Related]
5. Simultaneous activation of p53 and inhibition of XIAP enhance the activation of apoptosis signaling pathways in AML. Carter BZ; Mak DH; Schober WD; Koller E; Pinilla C; Vassilev LT; Reed JC; Andreeff M Blood; 2010 Jan; 115(2):306-14. PubMed ID: 19897582 [TBL] [Abstract][Full Text] [Related]
6. Nutlin-3 downregulates the expression of the oncogene TCL1 in primary B chronic lymphocytic leukemic cells. Voltan R; di Iasio MG; Bosco R; Valeri N; Pekarski Y; Tiribelli M; Secchiero P; Zauli G Clin Cancer Res; 2011 Sep; 17(17):5649-55. PubMed ID: 21753157 [TBL] [Abstract][Full Text] [Related]
8. Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Secchiero P; Barbarotto E; Tiribelli M; Zerbinati C; di Iasio MG; Gonelli A; Cavazzini F; Campioni D; Fanin R; Cuneo A; Zauli G Blood; 2006 May; 107(10):4122-9. PubMed ID: 16439677 [TBL] [Abstract][Full Text] [Related]
9. Comparison of the antitumor effects of an MDM2 inhibitor, nutlin-3, in feline lymphoma cell lines with or without p53 mutation. Mochizuki H; Goto-Koshino Y; Sato M; Fujino Y; Ohno K; Tsujimoto H Vet Immunol Immunopathol; 2012 Jun; 147(3-4):187-94. PubMed ID: 22578852 [TBL] [Abstract][Full Text] [Related]
11. Upregulation of SOCS-1 by Nutlin-3 in acute myeloid leukemia cells but not in primary normal cells. Tisato V; Norcio A; Celeghini C; Milani D; Gonelli A; Secchiero P Clinics (Sao Paulo); 2014 Jan; 69(1):68-74. PubMed ID: 24473562 [TBL] [Abstract][Full Text] [Related]
12. Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells. Miyachi M; Kakazu N; Yagyu S; Katsumi Y; Tsubai-Shimizu S; Kikuchi K; Tsuchiya K; Iehara T; Hosoi H Clin Cancer Res; 2009 Jun; 15(12):4077-84. PubMed ID: 19509161 [TBL] [Abstract][Full Text] [Related]
13. The combination of Nutlin-3 and Tanshinone IIA promotes synergistic cytotoxicity in acute leukemic cells expressing wild-type p53 by co-regulating MDM2-P53 and the AKT/mTOR pathway. Guo Y; Li Y; Wang FF; Xiang B; Huang XO; Ma HB; Gong YP Int J Biochem Cell Biol; 2019 Jan; 106():8-20. PubMed ID: 30389549 [TBL] [Abstract][Full Text] [Related]
14. Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells. Hasegawa H; Yamada Y; Iha H; Tsukasaki K; Nagai K; Atogami S; Sugahara K; Tsuruda K; Ishizaki A; Kamihira S Leukemia; 2009 Nov; 23(11):2090-101. PubMed ID: 19710698 [TBL] [Abstract][Full Text] [Related]
15. Activation of the p53 pathway induces α-smooth muscle actin expression in both myeloid leukemic cells and normal macrophages. Secchiero P; Rimondi E; di Iasio MG; Voltan R; Gonelli A; Zauli G J Cell Physiol; 2012 May; 227(5):1829-37. PubMed ID: 21732354 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma. Drakos E; Thomaides A; Medeiros LJ; Li J; Leventaki V; Konopleva M; Andreeff M; Rassidakis GZ Clin Cancer Res; 2007 Jun; 13(11):3380-7. PubMed ID: 17545546 [TBL] [Abstract][Full Text] [Related]
17. Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia. Kojima K; Konopleva M; Tsao T; Nakakuma H; Andreeff M Blood; 2008 Oct; 112(7):2886-95. PubMed ID: 18633130 [TBL] [Abstract][Full Text] [Related]
18. Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells. Kojima K; Konopleva M; Samudio IJ; Ruvolo V; Andreeff M Cancer Res; 2007 Apr; 67(7):3210-9. PubMed ID: 17409429 [TBL] [Abstract][Full Text] [Related]
19. MDM2 antagonist Nutlin-3 suppresses the proliferation and differentiation of human pre-osteoclasts through a p53-dependent pathway. Zauli G; Rimondi E; Corallini F; Fadda R; Capitani S; Secchiero P J Bone Miner Res; 2007 Oct; 22(10):1621-30. PubMed ID: 17592964 [TBL] [Abstract][Full Text] [Related]
20. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines. Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]